Lan Xu

Drug Discovery & Translational Medicine Advisor Polymed Biopharmaceuticals

Accomplished biologist with 14 years of experience in the biotech industry and academia. Strong background and expertise in oncology and rare disease drug discovery. Extensive experience in managing project teams and research groups. Core expertise in signal transduction, oncogenic kinases, and functional genomics with outstanding publications in top-tier scientific journals. Recognized expert in the TGFb field. Motivational and engaged team leader with excellent communication and interpersonal skills.

Seminars

Wednesday 18th March 2026
Showcasing KRas Degrader-Antibody Conjugates as a Therapeutic Approach for Treating KRas Driven Colorectal Cancer
11:00 am
  • Exploring how KRas degraders offer more complete KRas inhibition compared to small molecule inhibitors.
  • Showing how KRas degrader-Certuximab conjugate has unique advantages in treating KRas driven colorectal cancer
  • Highlighting Polymed’s KRas degrader and degrader-antibody conjugates demonstrated preclinical proof-of-concept
Lan Xu - 5th Novel Conjugates Summit